pravastatin sodium

CLINICAL USE

HMG CoA reductase inhibitor:Hypercholesterolaemia

DOSE IN NORMAL RENAL FUNCTION

10–40 mg daily at night

PHARMACOKINETICS

Molecular weight :446.5

%Protein binding :Approx 50

%Excreted unchanged in urine : 20

Volume of distribution (L/kg) :0.5

half-life – normal/ESRD (hrs) :1.5–2/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Unlikely to be dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antibacterials: increased risk of myopathy with daptomycin

Antivirals: concentration reduced by efavirenz

Ciclosporin: increased risk of myopathy Lipid lowering agents: increased risk of myopathy with fibrates, gemfibrozil (avoid) and nicotinic acid

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Rhabdomyolysis with acute renal failure, secondary to statin-induced myoglobinaemia, has been reportedInactive polar metabolite accumulates but is readily removed by haemodialysis

Tags: post-by-auto-php